Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Utpal Khambholja"'
Autor:
Ron Bose, Maureen E. Trudeau, José A. García-Sáenz, Adam Brufsky, Arlene Chan, Gavin Marx, Debu Tripathy, M. Thirlwell, Daniel Hunt, Utpal Khambholja, Manuel Ruiz-Borrego, Naisargee Shah, Carlos H. Barcenas, A. Jo Chien, Leanne McCulloch, Daniel Egle
Publikováno v:
Cancer Research. 81:PS13-20
Background: Neratinib (NERLYNX®), an irreversible pan-HER tyrosine kinase inhibitor, is used for the extended adjuvant treatment of patients with early-stage HER2-positive (HER2+) breast cancer following adjuvant trastuzumab-based therapy and for pa
Autor:
Daniel Egle, Christian F. Singer, Barbara Pistilli, Utpal Khambholja, José A. García-Sáenz, Maureen E. Trudeau, Feng Xu, Ron Bose, Daniel Hunt, Carlos H. Barcenas, Manuel Ruiz-Borrego, Adam Brufsky, Dieter Semsek, M. Thirlwell, K. A. Cheong, Johanna Wassermann, Naisargee Shah, Amy Jo Chien, Arlene Chan, Gavin Marx
Publikováno v:
Journal of Clinical Oncology. 39:536-536
536 Background: The primary tolerability concern with neratinib (NERLYNX®; N), an irreversible pan-HER tyrosine kinase inhibitor, is diarrhea. Data from the multi-cohort, open-label, phase 2 CONTROL trial [Barcenas et al. Ann Oncol 2020] demonstrate